TITLE

Mirabegron: A Review of Its Use in Patients with Overactive Bladder Syndrome

AUTHOR(S)
Sanford, Mark
PUB. DATE
August 2013
SOURCE
Drugs;2013, Vol. 73 Issue 11, p1213
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Mirabegron (YM178, Myrbetriq™, Betanis, Betmiga™) is a β-adrenergic receptor agonist approved in several countries for the symptomatic treatment of adults with overactive bladder syndrome. In three 12-week, randomized, double-blind, placebo-controlled, multinational trials in patients with overactive bladder syndrome, oral mirabegron 25 or 50 mg once daily significantly reduced the adjusted mean number of incontinence episodes per 24 h (in patients with incontinence at baseline) and the adjusted mean number of micturition episodes per 24 h (in full trial populations) [coprimary endpoints]. Across trials, mirabegron 50 mg once daily also consistently significantly reduced urgency episodes and increased the volume of urine voided per micturition, generally in association with improved health-related quality of life (HR-QOL) and treatment satisfaction. Based on descriptive analyses from a 12-month trial, once-daily mirabegron 50 mg and tolterodine extended-release (ER) 4 mg were both efficacious in reducing urinary symptoms and improving HR-QOL. Mirabegron was generally well tolerated in the trials. Over 12 weeks, the adverse event rate with mirabegron 50 mg once daily was similar to that with placebo. During 12 months of treatment, 2.8 % of mirabegron 50 mg once daily recipients reported dry mouth compared with 8.6 % with tolterodine ER 4 mg once daily recipients. Mirabegron 50 mg once daily carries a low risk of QT interval prolongation. Thus, mirabegron is an efficacious new treatment for overactive bladder syndrome with a favourable tolerability profile.
ACCESSION #
89093940

 

Related Articles

  • 2012 - Tiotropium improved lung function and delayed exacerbations in poorly controlled asthma. Greenstone, Michael // ACP Journal Club;12/18/2012, Vol. 157 Issue 12, p1 

    The article examines the effect of bronchodilator agent tiotropium brominein asthma patients when compared with standard combination therapy. It mentions the results of the clinical trials which concludes that the bronchodilator agent was effective in control of asthma in elderly patients. It...

  • Umeclidinium/Vilanterol: A Review of Its Use as Maintenance Therapy in Adults with Chronic Obstructive Pulmonary Disease. Blair, Hannah; Deeks, Emma // Drugs;Jan2015, Vol. 75 Issue 1, p61 

    Umeclidinium/vilanterol (Anoro Ellipta™; Laventair™) is an inhaled fixed-dose combination of a long-acting muscarinic receptor antagonist and a long-acting β-adrenoceptor agonist. It is available in several countries, including Japan, the USA, Canada and those of the EU, where it...

  • Turning a Molecule into a Medicine: the Development of Indacaterol as a Novel Once-Daily Bronchodilator Treatment for Patients with COPD. Murphy, Lorraine; Rennard, Stephen; Donohue, James; Molimard, Mathieu; Dahl, Ronald; Beeh, Kai-Michael; Dederichs, Juergen; Fülle, Hans-Jürgen; Higgins, Mark; Young, David // Drugs;Sep2014, Vol. 74 Issue 14, p1635 

    Indacaterol is the first once-daily, long-acting β-adrenergic agonist (LABA) approved for the treatment of chronic obstructive pulmonary disease (COPD). Indacaterol was developed using a combination of informed drug design and molecular chemistry to generate a β-adrenergic agonist with a...

  • Esmolol: A Review of its Use in the Short-Term Treatment of Tachyarrhythmias and the Short-Term Control of Tachycardia and Hypertension. Garnock-Jones, Karly P. // Drugs;2012, Vol. 72 Issue 1, p109 

    Supraventricular tachyarrhythmia (including atrial fibrillation), hypertension and tachycardia in the perioperative setting, and acute ischaemic heart disease are generally agreed to require rapid attention and treatment. Prolonged tachyarrhythmia or hypertension can result in significant...

  • The efficacy and tolerability of the β3-adrenoceptor agonist mirabegron for the treatment of symptoms of overactive bladder in older patients. Wagg, Adrian; Cardozo, Linda; Nitti, Victor W.; Castro-Diaz, David; Auerbach, Stephen; Blauwet, Mary Beth; Siddiqui, Emad // Age & Ageing;Sep2014, Vol. 43 Issue 5, p666 

    Introduction: mirabegron is a β3-adrenoceptor agonist developed for the treatment of symptoms of overactive bladder (OAB). As the prevalence of OAB increases with age, a prospective subanalysis of individual and pooled efficacy and tolerability data from three 12-week, randomised, Phase III...

  • Mirabegron -- promising new drug for overactive bladder syndrome. Rigby, Debbie // Australian & New Zealand Continence Journal;Winter2015, Vol. 21 Issue 2, p40 

    The article discusses the potential therapeutic use of antimuscarinic agent Mirabegron in treating patients with urinary incontinence (UI) and overactive bladder (OAB) syndrome. Information regarding the drugs adverse health effects, prescribed dosage, and tolerance, are discussed. The article...

  • Salmeterol and Fluticasone Propionate and Survival in Chronic Obstructive Pulmonary Disease. Calverley, Peter M.A.; Anderson, Julie A.; Celli, Bartolome; Ferguson, Gary T.; Jenkins, Christine; Jones, Paul W.; Yates, Julie C.; Vestbo, Jørgen // New England Journal of Medicine;2/22/2007, Vol. 356 Issue 8, p775 

    Background: Long-acting beta-agonists and inhaled corticosteroids are used to treat chronic obstructive pulmonary disease (COPD), but their effect on survival is unknown. Methods: We conducted a randomized, double-blind trial comparing salmeterol at a dose of 50 μg plus fluticasone propionate...

  • Effects of acute salbutamol intake during supramaximal exercise in women. Le Panse, Bénédicte; Arlettaz, Alexandre; Portier, Hugues; Lecoq, Anne-Marie; De Ceaurriz, Jacques; Collomp, Katia // British Journal of Sports Medicine;Jul2007, Vol. 41 Issue 7, p430 

    Objective: To study the effects of an acute therapeutic oral intake of β2 agonist on performance and substrate response during supramaximal exercise in women. Methods: 12 healthy moderately trained female volunteers performed a Wingate test after ingestion of placebo (Pla) and salbutamol...

  • Role of Esmolol in Perioperative Analgesia and Anesthesia: A Literature Review. Harless, Megan; Depp, Caleb; Collins, Shawn; Hewer, Ian // AANA Journal;Jun2015, Vol. 83 Issue 3, p167 

    The article discusses a literature review aimed at giving anesthesia providers evidence-based information for the use of esmolol as an anesthetic adjunct. Topics discussed include the potential of esmolol as an excellent agent in a multimodal approach to perioperative anesthetic management and...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics